Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency Diseases

NCT03116347 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT03116347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03116347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency Diseases
Lead sponsor
Baxalta now part of Shire
Phase
Phase 4
Overall status
Completed
Start date
May 30, 2017
Completion date
January 15, 2021
Enrollment
42 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency diseases (pid)